A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Phase of Trial: Phase II
Latest Information Update: 29 Jun 2016
At a glance
- Drugs Atorvastatin (Primary)
- Indications Hyperlipidaemia
- Focus Pharmacodynamics
- 07 Jun 2017 Biomarkers information updated
- 04 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Oct 2013 Planned end date changed from 1 Oct 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.